Skip to main content

Web Exclusives

Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
By Phoebe Starr
Conference Correspondent, In the News
Web Exclusives
Although tyrosine kinase inhibitors (TKIs), including imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel), have dramatically improved outcomes in patients with chronic myeloid leukemia (CML), the costs of these drugs have spiraled out of control, causing some patients to stop treatment or cut their dosage because of financial toxicity. Data presented at the 2016 American Society of Hematology meeting show that it is possible for some patients with CML to reduce their TKI dose by 50% and maintain remission, perhaps even stop treatment altogether once deep and durable remission has been achieved after approximately 5 years of treatment. Read More ›
Phoebe Starr
Barriers to Initiating Oral Oncolytics by Specialty Pharmacy or Payers Can Affect Patient Outcomes
By Leslie Wyatt
Supportive Care, In the News
Web Exclusives
Delaying medication processing is common, especially when it comes to oral cancer therapies. Oncologists at 3 oncology clinics looked at such barriers and the potential impact on patient outcomes. Read More ›
Leslie Wyatt
Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
By Wayne Kuznar
Conference Correspondent, In the News
Web Exclusives
Adding the investigational smoothened (SMO) receptor inhibitor glasdegib to low-dose cytarabine (Depo­Cyt) significantly increased overall survival (OS) compared with low-dose cytarabine monotherapy in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who were ineligible for intensive chemotherapy, according to a phase 2 study presented by Jorge E. Cortes, MD, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, at the 2016 American Society of Hematology meeting. Read More ›
Wayne Kuznar
New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs
By Chase Doyle
Conference Correspondent, In the News
Web Exclusives
A new economic model suggests that overall survival and drug toxicity profiles are insufficient for assessing the value of a drug. According to a study that incorporated late adverse events in advanced Hodgkin lymphoma, a more comprehensive benefit-to-risk ratio of a drug requires an understanding of its long-term health implications, said Ohad Oren, MD, Pennsylvania Hospital, University of Pennsylvania, Philadelphia, at the 2016 American Society of Hematology meeting. Read More ›
Chase Doyle
FDA Approves Rucaparib and Companion Diagnostic for Patients with Advanced Ovarian Cancer
FDA News & Updates, In the News
Web Exclusives
The FDA has granted accelerated approval of rucaparib (Rubraca), a poly ADP-ribose polymerase inhibitor, for the treatment of patients with advanced ovarian cancer whose tumors have deleterious BRCA gene mutation and have been treated with ≥2 chemotherapies. The administration also approved a companion diagnostic to the drug, FoundationFocus CDxBRCA, which is the first next-generation sequencing diagnostic test. Read More ›
Venclexta (Venetoclax) First BCL-2 Inhibitor Approved for High-Risk Relapsed Chronic Lymphocytic Leukemia
By Lisa A. Raedler, PhD, RPh, Medical Writer
Drug Updates
Web Exclusives
In April 2016, venetoclax (Venclexta; Janssen) became the first BCL-2 inhibitor to be approved by the FDA for relapsed, high-risk chronic lymphocytic leukemia. Read More ›
Lisa A. Raedler, PhD, RPh, Medical Writer
Daratumumab Combination Approved for Multiple Myeloma
FDA News & Updates, In the News
Web Exclusives
The FDA has granted approval to daratumumab (Darzalex) for the treatment of patients with multiple myeloma who have received ≥1 previous therapies, in combination with dexamethasone and either lenalidomide or bortezomib. Read More ›
Challenges in ALK-Positive NSCLC Management
By Meg Barbor, MPH
Conference Correspondent
Web Exclusives

Chicago, IL—The anaplastic lymphoma kinase (ALK) mutation is a target for tyrosine kinase therapies in several cancers, including non–small-cell lung cancer (NSCLC). Since 2011, several ALK inhibitors have been approved, and more are in the pipeline, but many questions remain for managing patients with ALK-positive NSCLC.

Read More ›
Meg Barbor, MPH
Lowering the High Cost of USP 800 Compliance
By Meg Barbor, MPH
Web Exclusives

Chicago, IL—Maintaining a clean room compliant with US Pharmacopeial Convention Chapter 800 (USP 800) can come with a significant price tag, but noncompliance can drive up costs to oncology practices and institutions. However, certain measures can contribute to the successful construction, renovation, and maintenance of hazardous drug sterile compounding spaces in an oncology setting, according to Ryan A. Forrey, PharmD, MS, FASHP, Director of Pharmacy, Emory University Hospital Midtown, Atlanta, GA.

Read More ›
Meg Barbor, MPH
Navigating the New Requirements for USP 800 Drugs
Conference Correspondent
Web Exclusives

Chicago, IL—A clear set of standard operating procedures is at the heart of US Pharmacopeial Convention Chapter 800 (USP 800) compliance, according to Carol Yarrington, PharmD, BCOP, Oncology and Infusion Pharmacy Coordinator and Clinical Oncology Pharmacist, St. Joseph Mercy Health System, Ann Arbor, MI.

Read More ›

Page 22 of 44